(Q63844518)

English

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310 (English)

0 references

0 references

1 reference

12 December 2021

https://clinicaltrials.gov/ct2/results?cond=&term=%22partial+thromboplastin+time%22

start time

8 May 2006

0 references

end time

21 November 2008

0 references

number of participants

301

0 references

research intervention

tamoxifen

0 references

clinical trial phase

phase III clinical trial

0 references

minimum age

40 year

0 references

maximum age

80 year

0 references

uses

partial thromboplastin time

1 reference

retrieved

12 December 2021

reference URL

https://clinicaltrials.gov/ct2/results?cond=&term=%22partial+thromboplastin+time%22

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT01586364

0 references

(Q63844518)

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)